The microbiota and the gut–liver axis in primary sclerosing cholangitis

Karlsen, T. H., Folseraas, T., Thorburn, D. & Vesterhus, M. Primary sclerosing cholangitis–a comprehensive review. J. Hepatol. 67, 1298–1323 (2017).

PubMed  Google Scholar 

Weismuller, T. J. et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 152, 1975–1984 (2017).

PubMed  Google Scholar 

Boonstra, K. et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58, 2045–2055 (2013).

CAS  PubMed  Google Scholar 

Karlsen, T. H., Schrumpf, E. & Boberg, K. M. Update on primary sclerosing cholangitis. Dig. Liver Dis. 42, 390–400 (2010).

CAS  PubMed  Google Scholar 

Jiang, X. & Karlsen, T. H. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat. Rev. Gastroenterol. Hepatol. 14, 279–295 (2017).

CAS  PubMed  Google Scholar 

Ji, S. G. et al. Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat. Genet. 49, 269–273 (2017).

CAS  PubMed  Google Scholar 

Liu, J. Z. et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat. Genet. 45, 670–675 (2013). Key study delineating the autoimmune genetic architecture of PSC.

CAS  PubMed  PubMed Central  Google Scholar 

Peng, X. et al. Immunosuppressive agents for the treatment of primary sclerosing cholangitis: a systematic review and meta-analysis. Dig. Dis. 35, 478–485 (2017).

PubMed  Google Scholar 

Albillos, A., de Gottardi, A. & Rescigno, M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J. Hepatol. 72, 558–577 (2020).

CAS  PubMed  Google Scholar 

Iliev, I. D. & Cadwell, K. Effects of intestinal fungi and viruses on immune responses and inflammatory bowel diseases. Gastroenterology 160, 1050–1066 (2021).

CAS  PubMed  Google Scholar 

Sokol, H. et al. Fungal microbiota dysbiosis in IBD. Gut 66, 1039–1048 (2017).

CAS  PubMed  Google Scholar 

de Vries, E. et al. Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma. Liver Int. 40, 3042–3050 (2020).

PubMed  Google Scholar 

Mouchli, M. A. et al. Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Inflamm. Bowel Dis. 24, 1074–1081 (2018).

PubMed  PubMed Central  Google Scholar 

Lunder, A. K. et al. Prevalence of sclerosing cholangitis, detected by magnetic resonance cholangiography, in patients with long-term inflammatory bowel disease. Gastroenterology 151, 660–669 (2016). First study to show that the prevalence of sclerosing cholangitis-like changes on MRC are more common than clinically overt PSC.

PubMed  Google Scholar 

Broome, U. & Bergquist, A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26, 31–41 (2006).

PubMed  Google Scholar 

Marelli, L. et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 60, 1224–1228 (2011).

PubMed  Google Scholar 

Navaneethan, U. et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 10, 540–546 (2012).

PubMed  Google Scholar 

Boden, R. W., Rankin, J. G., Goulston, S. J. & Morrow, W. The liver in ulcerative colitis: the significance of raised serum-alkaline-phosphatase levels. Lancet 2, 245–248 (1959).

CAS  PubMed  Google Scholar 

Rankin, J. G., Boden, R. W., Goulston, S. J. & Morrow, W. The liver in ulcerative colitis; treatment of pericholangitis with tetracycline. Lancet 2, 1110–1112 (1959).

CAS  PubMed  Google Scholar 

Farkkila, M. et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40, 1379–1386 (2004). First randomized clinical trial of antibiotics in PSC.

PubMed  Google Scholar 

Tabibian, J. H. et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis–a pilot study. Aliment. Pharmacol. Ther. 37, 604–612 (2013).

CAS  PubMed  Google Scholar 

Cangemi, J. R. et al. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96, 790–794 (1989).

CAS  PubMed  Google Scholar 

Martin, F. M. et al. Surgical aspects of sclerosing cholangitis. Results in 178 patients. Ann. Surg. 212, 551–556 (1990).

CAS  PubMed  PubMed Central  Google Scholar 

Nordenvall, C. et al. Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients. Aliment. Pharmacol. Ther. 47, 238–245 (2018).

CAS  PubMed  Google Scholar 

Vera, A. et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 360, 1943–1944 (2002).

PubMed  Google Scholar 

Graziadei, I. W. et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29, 1050–1056 (1999).

CAS  PubMed  Google Scholar 

Steenstraten, I. C. et al. Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Aliment. Pharmacol. Ther. 49, 636–643 (2019).

PubMed  PubMed Central  Google Scholar 

Peverelle, M., Paleri, S., Hughes, J., De Cruz, P. & Gow, P. J. Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes. Inflamm. Bowel Dis. 26, 1901–1908 (2020).

PubMed  Google Scholar 

Trivedi, P. J. et al. The impact of ileal pouch–anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 48, 322–332 (2018).

CAS  PubMed  Google Scholar 

Davies, Y. K. et al. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep. Transpl. 2013, 314292 (2013).

Google Scholar 

Hey, P., Lokan, J., Johnson, P. & Gow, P. Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep. 2017, bcr2017221165 (2017).

PubMed Central  Google Scholar 

Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in IL10−/− mice. Nature 487, 104–108 (2012).

CAS  PubMed  PubMed Central  Google Scholar 

Schwartz, D. J., Langdon, A. E. & Dantas, G. Understanding the impact of antibiotic perturbation on the human microbiome. Genome Med. 12, 82 (2020).

PubMed  PubMed Central  Google Scholar 

Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59–64 (2014).

CAS  PubMed  Google Scholar 

Acharya, C. & Bajaj, J. S. Chronic liver diseases and the microbiome — translating our knowledge of gut microbiota to management of chronic liver disease. Gastroenterology 160, 556–572 (2021).

PubMed  Google Scholar 

Wang, J. et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat. Genet. 48, 1396–1406 (2016).

CAS  PubMed  PubMed Central  Google Scholar 

Ruhlemann, M. C. et al. Genome-wide association study in 8,956 German individuals identifies influence of ABO histo-blood groups on gut microbiome. Nat. Genet. 53, 147–155 (2021).

PubMed  Google Scholar 

Lopera-Maya, E. A. et al. Effect of host genetics on the gut microbiome in 7738 participants of the Dutch Microbiome Project. Nat. Genet. 54, 143–151 (2022).

CAS  PubMed  Google Scholar 

Qin, Y. et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. Nat. Genet. 54, 134–142 (2022).

CAS  PubMed  Google Scholar 

Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014).

CAS  PubMed  PubMed Central  Google Scholar 

Xu, Z. & Knight, R. Dietary effects on human gut microbiome diversity. Br. J. Nutr. 113 (Suppl.), 1–5 (2015).

Google Scholar 

Vujkovic-Cvijin, I. et al. Host variables confound gut microbiota studies of human disease. Nature 587, 448–454 (2020).

CAS  PubMed  PubMed Central  Google Scholar 

Yap, C. X. et al. Autism-related dietary preferences mediate autism–gut microbiome associations. Cell 184, 5916–5931 (2021). Key study in highlighting the importance of confounding factors in assessing dietary impact on the gut microbiome.

CAS  PubMed  Google Scholar 

de Vries, E. M. et al. Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: an international cohort study. Hepatology 65, 907–919 (2017).

PubMed  Google Scholar 

Mazhar, A. & Russo, M. W. Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis. Aliment. Pharmacol. Ther. 53, 774–783 (2021).

PubMed  Google Scholar 

Fairfield, B. & Schnabl, B. Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Rep. 3, 100220 (2021).

PubMed  Google Scholar 

Aron-Wisnewsky, J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat. Rev. Gastroenterol. Hepatol. 17, 279–297 (2020).

PubMed  Google Scholar 

Iwasawa, K. et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis. Gut 66, 1344–1346 (2016).

留言 (0)

沒有登入
gif